for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alpine Immune Sciences Inc

ALPN.O

Latest Trade

10.38USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.05

 - 

15.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest News

BRIEF-Alpine Immune Sciences Inc Files For Mixed Shelf Of Up To $60 Mln

* ALPINE IMMUNE SCIENCES INC FILES FOR MIXED SHELF OF UP TO $60 MILLION - SEC FILING Source text: [https://bit.ly/2AGhcqG] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Alpine Immune Sciences Says Anticipate Having Enough Cash To Fund Planned Operations Into 2023

* ALPINE IMMUNE SCIENCES - ANTICIPATES HAVING ENOUGH CASH TO FUND PLANNED OPERATIONS INTO 2023, EXCLUDING REVENUE FROM EXISTING PARTNERSHIPS OR NEW ARRANGEMENTS

BRIEF-Alpine Immune Sciences And Abbvie Announce Option And License Agreement For Development And Commercialization Of ALPN-101

* ALPINE IMMUNE SCIENCES AND ABBVIE ANNOUNCE OPTION AND LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ALPN-101

BRIEF-Alpine Reports Qtrly Loss Per Share Of $0.30

* ALPINE IMMUNE SCIENCES REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

BRIEF-Alpine Immune Sciences Says Q4 Loss Per Share Of $0.33

* ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Alpine Immune Sciences’ Alpn-101 Receives FDA Orphan Drug Designations For The Prevention And Treatment Of Acute Graft Versus Host Disease

* ALPINE IMMUNE SCIENCES’ ALPN-101 RECEIVES FDA ORPHAN DRUG DESIGNATIONS FOR THE PREVENTION AND TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE Source text for Eikon: Further company coverage:

BRIEF-Alpine Immune Sciences Qtrly Loss Per Share $0.38

* ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Alpine Immune Sciences Appoints Chris Peetz To Its Board

* ALPINE IMMUNE SCIENCES APPOINTS LIFE SCIENCES EXECUTIVE CHRIS PEETZ TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Alpine Immune Sciences Provides Corporate Update And Reports Full Year 2017 Financial Results

* ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2017 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up